CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.
antigens
brain neoplasms
cell engineering
chimeric antigen
immunotherapy
neoplasm
receptors
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
accepted:
25
10
2021
entrez:
12
1
2022
pubmed:
13
1
2022
medline:
17
3
2022
Statut:
ppublish
Résumé
Glioblastoma (GBM) patients suffer from a dismal prognosis, with standard of care therapy inevitably leading to therapy-resistant recurrent tumors. The presence of cancer stem cells (CSCs) drives the extensive heterogeneity seen in GBM, prompting the need for novel therapies specifically targeting this subset of tumor-driving cells. Here, we identify CD70 as a potential therapeutic target for recurrent GBM CSCs. In the current study, we identified the relevance and functional influence of CD70 on primary and recurrent GBM cells, and further define its function using established stem cell assays. We use CD70 knockdown studies, subsequent RNAseq pathway analysis, and CD70 expression is elevated in recurrent GBM and CD70 knockdown reduces tumorigenicity CD70 plays a key role in recurrent GBM cell aggressiveness and maintenance. Immunotherapeutic targeting of CD70 significantly improves survival in animal models and the CD70/CD27 axis may be a viable polytherapeutic avenue to co-target both GBM and its TIME.
Identifiants
pubmed: 35017149
pii: jitc-2021-003289
doi: 10.1136/jitc-2021-003289
pmc: PMC8753449
pii:
doi:
Substances chimiques
CD27 Ligand
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: DU, DB and PV are employees of Century Therapeutics Canada. The other authors declare no competing interests.
Références
Semin Immunol. 1998 Oct;10(5):383-90
pubmed: 9799713
Cell Stem Cell. 2017 Jul 6;21(1):35-50.e9
pubmed: 28602620
J Clin Invest. 2017 Feb 1;127(2):415-426
pubmed: 28145904
Nature. 2006 Dec 7;444(7120):756-60
pubmed: 17051156
Am J Surg Pathol. 2000 May;24(5):742-6
pubmed: 10800994
Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):29-39
pubmed: 30419315
J Neurooncol. 2017 Oct;135(1):183-192
pubmed: 28730289
Cell Stem Cell. 2020 Jun 4;26(6):832-844.e6
pubmed: 32464096
Leukemia. 2014 Sep;28(9):1872-84
pubmed: 24569779
Nat Immunol. 2003 Jan;4(1):49-54
pubmed: 12469117
Sci Rep. 2018 Feb 14;8(1):2982
pubmed: 29445239
Expert Opin Ther Targets. 2016 Aug;20(8):959-73
pubmed: 26914723
BMC Bioinformatics. 2018 Nov 30;19(Suppl 15):436
pubmed: 30497369
Blood Cancer J. 2021 Apr 6;11(4):69
pubmed: 33824268
Sci Rep. 2015 Jan 27;5:7979
pubmed: 25623281
Cancer Res. 2012 Dec 1;72(23):6119-29
pubmed: 23071066
J Vis Exp. 2012 Sep 25;(67):
pubmed: 23051935
J Neuroinflammation. 2012 Sep 17;9:217
pubmed: 22985464
G3 (Bethesda). 2017 Aug 7;7(8):2719-2727
pubmed: 28655737
Cell. 2018 Aug 9;174(4):999-1014.e22
pubmed: 30096314
Science. 2018 May 11;360(6389):660-663
pubmed: 29748285
Clin Cancer Res. 2008 Jan 1;14(1):123-9
pubmed: 18172261
Hum Gene Ther. 2012 Oct;23(10):1043-53
pubmed: 22780919
Eur J Cancer. 2005 Aug;41(12):1794-801
pubmed: 16043348
Nat Commun. 2021 Feb 19;12(1):1151
pubmed: 33608526
Adv Exp Med Biol. 2017;1036:19-31
pubmed: 29275462
Immunology. 1997 Jan;90(1):38-45
pubmed: 9038710
Immunity. 2011 Feb 25;34(2):213-23
pubmed: 21349431
Int J Cancer. 2006 Apr 1;118(7):1728-35
pubmed: 16217761
Clin Cancer Res. 2017 Nov 1;23(21):6411-6420
pubmed: 28765328
Immunol Rev. 2009 May;229(1):216-31
pubmed: 19426224
Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585
pubmed: 29158380
Nature. 2010 Jan 21;463(7279):318-25
pubmed: 20032975
J Pathol. 2020 Feb;250(2):205-216
pubmed: 31639216
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Nat Cancer. 2021 Feb;2(2):157-173
pubmed: 35122077
J Immunol. 1994 Feb 15;152(4):1756-61
pubmed: 8120384
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
JCI Insight. 2018 May 17;3(10):
pubmed: 29769444
Expert Opin Ther Targets. 2008 Mar;12(3):341-51
pubmed: 18269343
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
Exp Hematol. 2005 Dec;33(12):1500-7
pubmed: 16338493
J Immunol. 2000 Apr 15;164(8):4097-104
pubmed: 10754303
Cancer Cell. 2015 Sep 14;28(3):318-28
pubmed: 26373279
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
Front Immunol. 2018 May 08;9:1004
pubmed: 29867979
Pancreatology. 2021 Apr;21(3):573-580
pubmed: 33541781
Clin Cancer Res. 2017 May 1;23(9):2267-2276
pubmed: 27803044
PLoS One. 2010 Nov 15;5(11):e13984
pubmed: 21085593
Nature. 2015 Nov 26;527(7579):525-530
pubmed: 26560028
Neuro Oncol. 2012 Sep;14(9):1178-84
pubmed: 22869622
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
J Neurooncol. 2017 Sep;134(3):505-512
pubmed: 28233083
Front Pediatr. 2021 Apr 30;9:615724
pubmed: 33996677
J Leukoc Biol. 2011 Feb;89(2):195-203
pubmed: 20699361
Sci Transl Med. 2019 Jan 2;11(473):
pubmed: 30602536
Genome Biol. 2020 Aug 26;21(1):216
pubmed: 32847614
Genomics Proteomics Bioinformatics. 2021 Feb;19(1):1-12
pubmed: 33662628
Nature. 2004 Nov 18;432(7015):396-401
pubmed: 15549107
Cancer Res. 2002 May 1;62(9):2592-9
pubmed: 11980654
CNS Neurosci Ther. 2020 Sep;26(9):981-989
pubmed: 32488994
Neuro Oncol. 2018 Jan 10;20(1):55-65
pubmed: 28651374
Oncotarget. 2015 May 30;6(15):13462-75
pubmed: 25951351
Curr Opin Oncol. 2015 Nov;27(6):466-74
pubmed: 26352543
Stem Cell Reports. 2015 Jul 14;5(1):1-9
pubmed: 26095605
Int J Cancer. 2019 Apr 15;144(8):1780-1785
pubmed: 30230539
Nat Immunol. 2005 Apr;6(4):412-8
pubmed: 15723067
Thromb Haemost. 2017 Jan 5;117(1):164-175
pubmed: 27786334
Cancer Res. 2005 Jun 15;65(12):5428-38
pubmed: 15958592
Oncogene. 2019 May;38(22):4384-4396
pubmed: 30710146
Cell Stem Cell. 2019 Jan 3;24(1):25-40
pubmed: 30595497
Neuro Oncol. 2017 Jan;19(1):139-141
pubmed: 28031383
Int Immunol. 1994 Mar;6(3):477-80
pubmed: 8186199
ESMO Open. 2020 Mar;4(Suppl 3):e000629
pubmed: 32152062
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Oncoimmunology. 2017 Dec 26;7(3):e1407898
pubmed: 29399409
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
Front Oncol. 2020 Feb 21;10:183
pubmed: 32154177
Int J Cancer. 2017 Oct 1;141(7):1434-1444
pubmed: 28612394
Nat Med. 2020 Sep;26(9):1459-1467
pubmed: 32601337
J Immunol. 2003 Jan 1;170(1):33-40
pubmed: 12496380
J Neurooncol. 2018 Apr;137(2):249-257
pubmed: 29302887
Cancer Cell. 2016 May 9;29(5):669-683
pubmed: 27165742
Curr Opin Immunol. 2005 Jun;17(3):275-81
pubmed: 15886117
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32759234
BMC Cancer. 2010 Mar 25;10:112
pubmed: 20338029
Cell. 2019 Aug 8;178(4):835-849.e21
pubmed: 31327527
Front Oncol. 2018 Feb 12;8:23
pubmed: 29484285
Cancer Cell Int. 2015 Mar 18;15:31
pubmed: 25792975
Oncogene. 2010 Aug 26;29(34):4741-51
pubmed: 20531305
Cell Mol Neurobiol. 2016 Oct;36(7):1067-76
pubmed: 26643178
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Cancer Med. 2020 Feb;9(3):1069-1078
pubmed: 31568682
Cell Rep. 2016 Dec 13;17(11):2994-3009
pubmed: 27974212
Int J Cancer. 2002 Mar 20;98(3):352-6
pubmed: 11920585
Cancer Discov. 2020 Aug;10(8):1210-1225
pubmed: 32300059
Mol Med Rep. 2018 Jul;18(1):741-748
pubmed: 29767255
J Immunol. 2008 Mar 15;180(6):3739-45
pubmed: 18322179
Biomark Res. 2017 Jun 24;5:22
pubmed: 28652918
Nat Med. 2020 Jan;26(1):39-46
pubmed: 31873309
Oncotarget. 2018 Apr 10;9(27):19123-19135
pubmed: 29721188
Blood. 2019 May 23;133(21):2291-2304
pubmed: 30796021
Sci Transl Med. 2017 Jul 19;9(399):
pubmed: 28724573
Br J Cancer. 2016 Jan 12;114(1):63-70
pubmed: 26671750
Sci Rep. 2020 Oct 16;10(1):17580
pubmed: 33067480
Br J Cancer. 2006 Aug 7;95(3):298-306
pubmed: 16892042
J Immunol. 2004 May 15;172(10):6039-46
pubmed: 15128787
Cells. 2017 Nov 22;6(4):
pubmed: 29165393
Neurosurg Clin N Am. 2017 Jul;28(3):407-428
pubmed: 28600015
Br J Haematol. 1999 Aug;106(2):491-503
pubmed: 10460611
Blood. 2011 Apr 21;117(16):4304-14
pubmed: 21304103
Mol Cancer. 2006 Dec 02;5:67
pubmed: 17140455
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Leukemia. 2018 Sep;32(9):1970-1983
pubmed: 29483708
Science. 2020 Nov 13;370(6518):
pubmed: 33184181
Neoplasia. 2006 Nov;8(11):933-8
pubmed: 17132225
Mol Cancer Ther. 2008 Sep;7(9):2913-23
pubmed: 18790772
Front Oncol. 2013 Nov 11;3:275
pubmed: 24273748
EMBO J. 2020 Sep 1;39(17):e103209
pubmed: 32692442
Breast Cancer. 2018 Nov;25(6):706-716
pubmed: 29948958
Oncology. 2019;97(6):365-372
pubmed: 31533124
Oncoimmunology. 2015 May 29;4(12):e1049805
pubmed: 26587319
Front Oncol. 2020 Apr 24;10:494
pubmed: 32391260
J Biotechnol. 2010 Jul 1;148(1):3-15
pubmed: 20097238
J Immunol. 2006 Feb 1;176(3):1517-24
pubmed: 16424180
J Immunol. 2014 Jul 15;193(2):871-8
pubmed: 24913981
Cancer Res. 2012 Jul 15;72(14):3664-76
pubmed: 22628427
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Int J Cardiol. 2018 Jun 1;260:184-190
pubmed: 29622436
Front Immunol. 2018 Feb 02;9:152
pubmed: 29456539